Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study
OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries. METHODS: PsA patients registered in the...
Published in: | Rheumatology |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://vbn.aau.dk/da/publications/766417d4-8539-4470-a959-434627cb71bf https://doi.org/10.1093/rheumatology/keaa237 http://www.scopus.com/inward/record.url?scp=85099428843&partnerID=8YFLogxK |
id |
ftalborgunivpubl:oai:pure.atira.dk:publications/766417d4-8539-4470-a959-434627cb71bf |
---|---|
record_format |
openpolar |
spelling |
ftalborgunivpubl:oai:pure.atira.dk:publications/766417d4-8539-4470-a959-434627cb71bf 2024-10-13T14:08:30+00:00 Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study Lund Hansen, Rebekka Schoedt Jørgensen, Tanja Dreyer, Lene Hetland, Merete L Glintborg, Bente Askling, Johan Di Giuseppe, Daniela Jacobsson, Lennart T H Wallman, Johan K Nordstrom, Dan Aaltonen, Kalle Kristianslund, Eirik K Kvien, Tore K Provan, Sella A Gudbjornsson, Bjorn Love, Thorvadur J Kristensen, L E 2021-01 https://vbn.aau.dk/da/publications/766417d4-8539-4470-a959-434627cb71bf https://doi.org/10.1093/rheumatology/keaa237 http://www.scopus.com/inward/record.url?scp=85099428843&partnerID=8YFLogxK eng eng https://vbn.aau.dk/da/publications/766417d4-8539-4470-a959-434627cb71bf info:eu-repo/semantics/closedAccess Lund Hansen , R , Schoedt Jørgensen , T , Dreyer , L , Hetland , M L , Glintborg , B , Askling , J , Di Giuseppe , D , Jacobsson , L T H , Wallman , J K , Nordstrom , D , Aaltonen , K , Kristianslund , E K , Kvien , T K , Provan , S A , Gudbjornsson , B , Love , T J & Kristensen , L E 2021 , ' Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics : a Nordic population-based cohort study ' , Rheumatology , vol. 60 , no. 1 , keaa237 , pp. 140–146 . https://doi.org/10.1093/rheumatology/keaa237 bDMARDs international collaborations prescription patterns psoriatic arthritis secular trends of inflammatory hallmarks article 2021 ftalborgunivpubl https://doi.org/10.1093/rheumatology/keaa237 2024-09-19T00:52:41Z OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries. METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment. RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association. CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype. Article in Journal/Newspaper Iceland Aalborg University's Research Portal Norway Rheumatology 60 1 140 146 |
institution |
Open Polar |
collection |
Aalborg University's Research Portal |
op_collection_id |
ftalborgunivpubl |
language |
English |
topic |
bDMARDs international collaborations prescription patterns psoriatic arthritis secular trends of inflammatory hallmarks |
spellingShingle |
bDMARDs international collaborations prescription patterns psoriatic arthritis secular trends of inflammatory hallmarks Lund Hansen, Rebekka Schoedt Jørgensen, Tanja Dreyer, Lene Hetland, Merete L Glintborg, Bente Askling, Johan Di Giuseppe, Daniela Jacobsson, Lennart T H Wallman, Johan K Nordstrom, Dan Aaltonen, Kalle Kristianslund, Eirik K Kvien, Tore K Provan, Sella A Gudbjornsson, Bjorn Love, Thorvadur J Kristensen, L E Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study |
topic_facet |
bDMARDs international collaborations prescription patterns psoriatic arthritis secular trends of inflammatory hallmarks |
description |
OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries. METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment. RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association. CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype. |
format |
Article in Journal/Newspaper |
author |
Lund Hansen, Rebekka Schoedt Jørgensen, Tanja Dreyer, Lene Hetland, Merete L Glintborg, Bente Askling, Johan Di Giuseppe, Daniela Jacobsson, Lennart T H Wallman, Johan K Nordstrom, Dan Aaltonen, Kalle Kristianslund, Eirik K Kvien, Tore K Provan, Sella A Gudbjornsson, Bjorn Love, Thorvadur J Kristensen, L E |
author_facet |
Lund Hansen, Rebekka Schoedt Jørgensen, Tanja Dreyer, Lene Hetland, Merete L Glintborg, Bente Askling, Johan Di Giuseppe, Daniela Jacobsson, Lennart T H Wallman, Johan K Nordstrom, Dan Aaltonen, Kalle Kristianslund, Eirik K Kvien, Tore K Provan, Sella A Gudbjornsson, Bjorn Love, Thorvadur J Kristensen, L E |
author_sort |
Lund Hansen, Rebekka |
title |
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study |
title_short |
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study |
title_full |
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study |
title_fullStr |
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study |
title_full_unstemmed |
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a Nordic population-based cohort study |
title_sort |
inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics:a nordic population-based cohort study |
publishDate |
2021 |
url |
https://vbn.aau.dk/da/publications/766417d4-8539-4470-a959-434627cb71bf https://doi.org/10.1093/rheumatology/keaa237 http://www.scopus.com/inward/record.url?scp=85099428843&partnerID=8YFLogxK |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Lund Hansen , R , Schoedt Jørgensen , T , Dreyer , L , Hetland , M L , Glintborg , B , Askling , J , Di Giuseppe , D , Jacobsson , L T H , Wallman , J K , Nordstrom , D , Aaltonen , K , Kristianslund , E K , Kvien , T K , Provan , S A , Gudbjornsson , B , Love , T J & Kristensen , L E 2021 , ' Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics : a Nordic population-based cohort study ' , Rheumatology , vol. 60 , no. 1 , keaa237 , pp. 140–146 . https://doi.org/10.1093/rheumatology/keaa237 |
op_relation |
https://vbn.aau.dk/da/publications/766417d4-8539-4470-a959-434627cb71bf |
op_rights |
info:eu-repo/semantics/closedAccess |
op_doi |
https://doi.org/10.1093/rheumatology/keaa237 |
container_title |
Rheumatology |
container_volume |
60 |
container_issue |
1 |
container_start_page |
140 |
op_container_end_page |
146 |
_version_ |
1812815180219809792 |